Standard Operating Procedure: Conducting a Randomized Controlled Trial (RCT)

Introduction

Executing a Randomized Controlled Trial (RCT) is the gold standard for establishing causal relationships in clinical and social science research. As an operations manager, the objective of this SOP is to ensure rigorous adherence to study protocols, data integrity, and ethical compliance. This document serves as a comprehensive checklist to minimize systematic bias, ensure reproducibility, and maintain participant safety from the pre-trial phase through final data lock.

---

Phase 1: Preparation and Regulatory Compliance

• Protocol Finalization: Ensure the study protocol is finalized, including clear primary and secondary endpoints, sample size calculations, and power analysis.
• IRB/Ethics Approval: Secure formal approval from the Institutional Review Board (IRB) or Ethics Committee.
• Clinical Trial Registration: Register the trial on a public registry (e.g., ClinicalTrials.gov) prior to the enrollment of the first participant.
• Informed Consent Forms (ICF): Prepare and approve site-specific ICFs that detail risks, benefits, and the right to withdraw.
• Data Management Plan (DMP): Establish secure, HIPAA/GDPR-compliant infrastructure for electronic Case Report Form (eCRF) entry.

Phase 2: Recruitment and Randomization

• Screening Logs: Maintain a strictly documented screening log to track reasons for screen failures.
• Eligibility Verification: Ensure all participants meet strict inclusion/exclusion criteria before randomization.
• Randomization Sequence: Implement a computer-generated, opaque randomization sequence (stratified if necessary).
• Blinding/Masking: Confirm that investigators, participants, and outcome assessors are masked according to the protocol (e.g., double-blind or triple-blind procedures).
• Allocation Concealment: Ensure the randomization process is concealed from those recruiting participants to prevent selection bias.

Phase 3: Intervention and Monitoring

• Baseline Assessment: Document comprehensive baseline demographics and clinical history before the administration of the intervention.
• Adherence Monitoring: Implement methods to track intervention compliance (e.g., medication diaries, blood markers, or app-based tracking).
• Adverse Event (AE) Reporting: Establish a real-time system for recording, grading, and reporting Serious Adverse Events (SAEs) to the regulatory authority within 24–72 hours.
• Site Monitoring Visits: Conduct regular audits to ensure staff are following the "Good Clinical Practice" (GCP) guidelines.

Phase 4: Data Analysis and Closure

• Statistical Analysis Plan (SAP): Finalize the SAP before unblinding the study data.
• Data Cleaning: Perform logical range checks and query all missing or anomalous data entries.
• Database Lock: Formally lock the database; ensure no changes can be made prior to unblinding.
• Intent-to-Treat (ITT) Analysis: Ensure the primary analysis follows the ITT principle to prevent bias from participant attrition.
• Final Reporting: Draft the final report following CONSORT (Consolidated Standards of Reporting Trials) guidelines.

---

Pro Tips & Pitfalls

• Pro Tip: Use an interactive voice/web response system (IVRS/IWRS) for randomization to ensure absolute allocation concealment and immediate, timestamped documentation.
• Pitfall - Attrition Bias: Failing to account for dropouts is the most common cause of underpowered studies. Build a "dropout buffer" (e.g., 10-20% extra) into your initial sample size calculation.
• Pro Tip: Conduct a "Dry Run" pilot phase with 3-5 participants to identify bottlenecks in your eCRF or consent workflow before scaling up.
• Pitfall - Protocol Deviations: Even minor deviations from the protocol (e.g., wrong dosage timing) can invalidate data. Maintain a "Protocol Deviation Log" and review it weekly with the site team.

---

FAQ

Q: What is the most critical step to prevent selection bias in an RCT? A: Allocation concealment. Even if the randomization sequence is truly random, if those recruiting participants know what the next assignment will be, they may subconsciously influence who enters the study, compromising the balance between groups.

Q: Why is an "Intent-to-Treat" (ITT) analysis preferred over "Per-Protocol" analysis? A: ITT preserves the benefit of randomization by analyzing participants based on the group they were originally assigned to, regardless of whether they dropped out or were non-compliant. Per-protocol analysis often leads to overly optimistic results by excluding participants who did not adhere to the regimen.

Q: What defines a "Serious Adverse Event" (SAE)? A: An SAE is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization, results in persistent disability, or causes a congenital anomaly. All SAEs must be reported immediately to the oversight board regardless of suspected causality.